Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Inhibition of Y box binding protein 1 suppresses cell growth and motility in colorectal cancer.

Kim A, Shim S, Kim YH, Kim MJ, Park S, Myung JK.

Mol Cancer Ther. 2019 Oct 31. pii: molcanther.0265.2019. doi: 10.1158/1535-7163.MCT-19-0265. [Epub ahead of print]

PMID:
31672764
2.

Knockdown of Y‑box‑binding protein‑1 inhibits the malignant progression of HT‑29 colorectal adenocarcinoma cells by reversing epithelial‑mesenchymal transition.

Yan XB, Zhu QC, Chen HQ, Peng JY, Chao HL, Du HX, Wang ZG, Jin ZM.

Mol Med Rep. 2014 Nov;10(5):2720-8. doi: 10.3892/mmr.2014.2545. Epub 2014 Sep 5.

PMID:
25201740
3.

Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.

Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S.

Int J Cancer. 2013 Aug 15;133(4):984-96. doi: 10.1002/ijc.28073. Epub 2013 Mar 8.

4.

Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.

Wang Y, Chen Y, Geng H, Qi C, Liu Y, Yue D.

Tumour Biol. 2015 Sep;36(9):7159-66. doi: 10.1007/s13277-015-3417-z. Epub 2015 Apr 17.

PMID:
25877750
5.

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.

Chen YH, Wei MF, Wang CW, Lee HW, Pan SL, Gao M, Kuo SH, Cheng AL, Teng CM.

Cancer Lett. 2015 Feb 28;357(2):582-90. doi: 10.1016/j.canlet.2014.12.015. Epub 2014 Dec 10.

PMID:
25497009
6.

GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro.

Zhang X, Ding Z, Mo J, Sang B, Shi Q, Hu J, Xie S, Zhan W, Lu D, Yang M, Bian W, Zhou X, Yu R.

Mol Carcinog. 2015 Nov;54(11):1252-63. doi: 10.1002/mc.22197. Epub 2014 Aug 23.

PMID:
25156912
7.

IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways.

Duan S, Huang W, Liu X, Liu X, Chen N, Xu Q, Hu Y, Song W, Zhou J.

J Exp Clin Cancer Res. 2018 Dec 5;37(1):304. doi: 10.1186/s13046-018-0980-3.

8.

The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway.

Zhang JJ, Xu WR, Chen B, Wang YY, Yang N, Wang LJ, Zhang YL.

Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8321-8331. doi: 10.26355/eurrev_201910_19143.

9.

Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor.

Aung W, Tsuji AB, Sudo H, Sugyo A, Ukai Y, Kouda K, Kurosawa Y, Furukawa T, Saga T, Higashi T.

World J Gastroenterol. 2017 Nov 14;23(42):7551-7562. doi: 10.3748/wjg.v23.i42.7551.

10.
11.

Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse.

Mylona E, Melissaris S, Giannopoulou I, Theohari I, Papadimitriou C, Keramopoulos A, Nakopoulou L.

Eur J Surg Oncol. 2014 Mar;40(3):289-96. doi: 10.1016/j.ejso.2013.09.008. Epub 2013 Sep 15.

PMID:
24075827
12.

MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.

Shi L, Xi J, Xu X, Peng B, Zhang B.

Biomed Pharmacother. 2019 Jan;109:902-909. doi: 10.1016/j.biopha.2018.10.080. Epub 2018 Nov 5.

13.

Elevated expression of G3BP1 associates with YB1 and p-AKT and predicts poor prognosis in nonsmall cell lung cancer patients after surgical resection.

Zheng H, Zhan Y, Zhang Y, Liu S, Lu J, Yang Y, Wen Q, Fan S.

Cancer Med. 2019 Nov;8(16):6894-6903. doi: 10.1002/cam4.2579. Epub 2019 Sep 27.

14.

Overexpression of YB1 C-terminal domain inhibits proliferation, angiogenesis and tumorigenicity in a SK-BR-3 breast cancer xenograft mouse model.

Shi JH, Cui NP, Wang S, Zhao MZ, Wang B, Wang YN, Chen BP.

FEBS Open Bio. 2016 Jan 11;6(1):33-42. doi: 10.1002/2211-5463.12004. eCollection 2016 Jan.

15.

FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.

Lin A, Piao HL, Zhuang L, Sarbassov dos D, Ma L, Gan B.

Cancer Res. 2014 Mar 15;74(6):1682-93. doi: 10.1158/0008-5472.CAN-13-1729. Epub 2014 Jan 21.

16.

YB1 binds to and represses the p16 tumor suppressor gene.

Kotake Y, Ozawa Y, Harada M, Kitagawa K, Niida H, Morita Y, Tanaka K, Suda T, Kitagawa M.

Genes Cells. 2013 Nov;18(11):999-1006. doi: 10.1111/gtc.12093. Epub 2013 Sep 24.

18.

Y-Box binding protein 1 expression in breast cancer and its correlation with hormone receptors and other prognostic markers.

Bansal T, Tanveer N, Singh UR, Sharma S, Kaur N.

J Lab Physicians. 2018 Oct-Dec;10(4):420-425. doi: 10.4103/JLP.JLP_58_18.

19.

Overexpressed ACP5 has prognostic value in colorectal cancer and promotes cell proliferation and tumorigenesis via FAK/PI3K/AKT signaling pathway.

Bian ZQ, Luo Y, Guo F, Huang YZ, Zhong M, Cao H.

Am J Cancer Res. 2019 Jan 1;9(1):22-35. eCollection 2019.

20.

microRNA-532 suppresses the PI3K/Akt signaling pathway to inhibit colorectal cancer progression by directly targeting IGF-1R.

Song Y, Zhao Y, Ding X, Wang X.

Am J Cancer Res. 2018 Mar 1;8(3):435-449. eCollection 2018.

Supplemental Content

Support Center